Who
Jean-Pierre Sommadossi
President, CEO, and Chairman
Company insider
Files Form 4 as: President, CEO, and Chairman, Atea Pharmaceuticals; Director, ABG Acquisition Corp. I; Director, Kezar Life Sciences; President, CEO, Chairman, Idenix Pharmaceuticals.
In numbers
- Trades disclosed
- 50
- Buys
- 1
- Sells
- 5
- Bought
- $91K
- Sold
- $457K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 6 Apr 2005
- Last trade
- 3 Feb 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Feb 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $372K300,000 at $1.24 | filing |
| 3 Feb 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —300,000 at $0.00 | filing |
| 3 Feb 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —300,000 at $0.00 | filing |
| 3 Feb 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $372K300,000 at $1.24 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —272,983 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $450K106,093 at $4.24 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —173,466 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —99,517 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —173,466 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —99,517 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —272,983 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $450K106,093 at $4.24 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —173,467 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —99,518 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —440,000 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —173,467 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —99,517 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $271K88,601 at $3.06 | filing |
| 19 Sep 2024filed 19 Sep 2024 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,3641,841 at $4.00 | filing |
| 18 Sep 2024filed 19 Sep 2024 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $89K22,187 at $4.03 | filing |
News
No headline names them, or the companies they trade most, lately.